home · filing · 0001213900-22-038536
8-K filed July 11, 2022, 7:59 PM ET
ticker ALLR
CIK 0001860657
leadership
confidence high
sentiment neutral
materiality 0.50
Allarity appoints three new directors, expands board from 4 to 6 members
Allarity Therapeutics, Inc.
Board size increased to 6; new directors: David Roth (independent), James Cullem (Interim CEO), Thomas Jensen (co-founder, SVP IR).
David Roth, M.D., brings 25+ years oncology drug development experience; currently CMO of Syros Pharmaceuticals.
Bylaws amended: stockholder quorum reduced from majority to 33.33% of voting power.
Independent director annual retainer raised to $50,000; Roth received options for 23,000 shares at $1.28.
Cullem continues as CEO and Chief Business Officer; Jensen as SVP Investor Relations.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2022-07-07
Filed July 11, 2022, 7:59 PM ET
Class III Director : James G. Cullem, whose term will expire at the Company’s third annual meeting of stockholders to be held after December 2021
Effective 2022-07-07
Filed July 11, 2022, 7:59 PM ET
Class II Director : Dr. David Roth, whose term will expire at the Company’s second annual meeting of stockholders to be held after December 2021
Effective 2022-07-07
Filed July 11, 2022, 7:59 PM ET
Class I Director : Thomas Jensen, whose term will expire at the Company’s first annual meeting of stockholders held after December 2021
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
James G. Cullem was appointed as Director at Allarity Therapeutics, Inc..
Action appointed
Role Director
Exact text from the filing
Class III Director : James G. Cullem, whose term will expire at the Company’s third annual meeting of stockholders to be held after December 2021
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David Roth was appointed as Director at Allarity Therapeutics, Inc..
Action appointed
Role Director
Exact text from the filing
Class II Director : Dr. David Roth, whose term will expire at the Company’s second annual meeting of stockholders to be held after December 2021
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Thomas Jensen was appointed as Director at Allarity Therapeutics, Inc..
Action appointed
Role Director
Exact text from the filing
Class I Director : Thomas Jensen, whose term will expire at the Company’s first annual meeting of stockholders held after December 2021
View on SEC.gov
Source: SEC EDGAR
accession 0001213900-22-038536
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.